(0.30%) 5 115.29 points
(0.20%) 38 316 points
(0.29%) 15 974 points
(-1.42%) $82.66
(3.38%) $1.988
(0.13%) $2 350.20
(0.15%) $27.58
(3.31%) $952.65
(-0.08%) $0.934
(-0.09%) $11.02
(-0.33%) $0.798
(1.76%) $93.49
Live Chart Being Loaded With Signals
JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan...
Stats | |
---|---|
Dagens volum | 800 300 |
Gjennomsnittsvolum | 720 063 |
Markedsverdi | 99.47B |
EPS | ¥0 ( 2024-01-25 ) |
Neste inntjeningsdato | ( ¥16.69 ) 2024-05-08 |
Last Dividend | ¥10.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 18.62 |
ATR14 | ¥0.642 (0.08%) |
Volum Korrelasjon
JCR Pharmaceuticals Co., Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
JCR Pharmaceuticals Co., Korrelasjon - Valuta/Råvare
JCR Pharmaceuticals Co., Økonomi
Annual | 2022 |
Omsetning: | ¥34.34B |
Bruttogevinst: | ¥25.46B (74.13 %) |
EPS: | ¥30.34 |
FY | 2022 |
Omsetning: | ¥34.34B |
Bruttogevinst: | ¥25.46B (74.13 %) |
EPS: | ¥30.34 |
FY | 2022 |
Omsetning: | ¥51.08B |
Bruttogevinst: | ¥40.62B (79.52 %) |
EPS: | ¥117.26 |
FY | 2021 |
Omsetning: | ¥30.09B |
Bruttogevinst: | ¥22.27B (74.03 %) |
EPS: | ¥55.81 |
Financial Reports:
No articles found.
JCR Pharmaceuticals Co., Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥10.00 (N/A) |
¥0 (N/A) |
¥10.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥1.250 | 2007-09-25 |
Last Dividend | ¥10.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 30 | -- |
Total Paid Out | ¥100.88 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.56 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.40 | |
Div. Directional Score | 7.52 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8570.T | Ex Dividend Knight | 2023-08-30 | Semi-Annually | 0 | 0.00% | |
7905.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7059.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6370.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
5288.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4346.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
3513.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
2742.T | Ex Dividend Knight | 2024-02-28 | Semi-Annually | 0 | 0.00% | |
9632.T | Ex Dividend Knight | 2024-01-30 | Semi-Annually | 0 | 0.00% | |
8168.T | Ex Dividend Junior | 2024-02-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.130 | 1.500 | 7.41 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0522 | 1.200 | 8.26 | 9.91 | [0 - 0.3] |
returnOnEquityTTM | 0.0987 | 1.500 | -0.0142 | -0.0213 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.801 | 0.800 | 6.00 | 4.80 | [1 - 3] |
quickRatioTTM | 1.084 | 0.800 | 8.33 | 6.67 | [0.8 - 2.5] |
cashRatioTTM | 0.573 | 1.500 | 7.93 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.227 | -1.500 | 6.22 | -9.33 | [0 - 0.6] |
interestCoverageTTM | 105.82 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 45.13 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 45.13 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.419 | -1.500 | 8.33 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.748 | 1.000 | 0.861 | 0.861 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.189 | 1.000 | 8.21 | 8.21 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.242 | 1.000 | 9.77 | 9.77 | [0.2 - 2] |
assetTurnoverTTM | 0.402 | 0.800 | -0.650 | -0.520 | [0.5 - 2] |
Total Score | 10.65 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 18.54 | 1.000 | 8.23 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0987 | 2.50 | -0.00912 | -0.0213 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 45.13 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.51 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 45.13 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.168 | 1.500 | -2.21 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.136 | 1.000 | 9.10 | 0 | [0.1 - 0.5] |
Total Score | 4.40 |
JCR Pharmaceuticals Co.,
JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.